Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Amino Acids ; 38(1): 329-37, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19267182

ABSTRACT

3-Aza-6,8-dioxabicyclo[3.2.1]octane-based amino acids as reverse turn inducers have been introduced into cyclic peptidomimetics containing the RGD or DGR retro-sequence, in order to achieve a stereochemical scanning of the binding capability of the resulting molecules towards alpha(v)beta(3) and alpha(v)beta(5) integrins, resulting in retro-inverso DGR peptides as micromolar ligands. A comparative analysis between the conformational preferences of 4 and of its isomer 3, having the opposite RGD sequence, was reported with respect to the binding activity, giving insight into the factors affecting the preferential binding of 4 to the alpha(v)beta(5) integrin.


Subject(s)
Peptides, Cyclic/chemistry , Receptors, Vitronectin/chemistry , Female , Humans , Kinetics , Ligands , Peptides, Cyclic/agonists , Peptides, Cyclic/chemical synthesis , Placenta/chemistry , Placenta/metabolism , Pregnancy , Protein Binding , Receptors, Vitronectin/metabolism
2.
Bioorg Med Chem ; 9(12): 3197-206, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11711295

ABSTRACT

The synthesis and a preliminary biological characterization of a new class of N-benzyl-aminoalcohols which have serotonin (5-HT(2)) and dopamine (D(2)) receptor affinity is described. In vitro competition binding studies were conducted with the new molecules and (3)H-spiperone on crude membrane preparation from rat striatum and frontal cortex. One of these compounds, 3-benzylamino-1-(4-fluoro-2-iodophenyl)-propan-1-ol (6f), whose IC(50) values are in the micromolar range for both the D(2) and 5-HT(2) receptors, was prepared in iodine-125 labelled form (6i) by nucleophilic substitution of the bromine atom of 3-benzylamino-1-(2-bromo-4-fluorophenyl)-propan-1-ol (6d). In the in vivo studies, conducted on rats, the radiolabelled molecule 6i shows a good capacity to cross the blood-brain barrier (BBB) with a mean value of first pass cerebral extraction (E) of ca. 50% when the regional cerebral blood flow, measured with microsphere technique, is in the experimental animal's physiologic range (0.8-1 mL/min/g). A preliminary in vitro autoradiographic distribution on coronal rat brain slices of the radioiodinated molecule showed that it was preferentially localized in the striatum and in the cerebral regions rich in dopamine- and serotonin receptors, even if a high non-specific binding was observed.


Subject(s)
Iodine Radioisotopes/chemistry , Propanols/chemical synthesis , Receptors, Dopamine D2/metabolism , Receptors, Serotonin/metabolism , Animals , Blood-Brain Barrier , Brain/metabolism , Drug Evaluation, Preclinical , In Vitro Techniques , Inhibitory Concentration 50 , Iodine Radioisotopes/pharmacokinetics , Male , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
3.
Nucl Med Biol ; 25(3): 289-93, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9620635

ABSTRACT

Central dopaminergic receptors are widely studied for their importance in the pathophysiology of neurological and psychiatric diseases. We have investigated the cerebral delivery kinetics of three dopaminergic ligands in rats through the use of an indicator fractionation method to measure the tracer's regional influx rate constant with respect to regional blood flow. The aim is to collect the in vivo kinetic parameters of the radioligand cerebral distribution, which are necessary if, dealing with SPECT and "trapped" tracers, one wishes to analyse data using a graphical approach.


Subject(s)
Benzamides/pharmacokinetics , Brain/metabolism , Dopamine Agonists/pharmacokinetics , Iodine Radioisotopes/pharmacokinetics , Pyrrolidines/pharmacokinetics , Salicylamides/pharmacokinetics , Tomography, Emission-Computed, Single-Photon , Animals , Brain/blood supply , Brain/diagnostic imaging , Cerebrovascular Circulation , Male , Radioligand Assay , Rats , Rats, Sprague-Dawley , Regional Blood Flow , Technetium/pharmacokinetics
5.
J Cereb Blood Flow Metab ; 14 Suppl 1: S28-35, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8263068

ABSTRACT

This study describes and validates in a preliminary manner a method to measure the steady-state influx constant (Ki) of 99mTc-bicisate with one single photon emission computed tomography (SPECT) scan. The method is based on the analysis of the arterial concentration of the radioactivity. The results of this quantitation procedure were compared with regional CBF (rCBF) measurements made using 99mTc-microspheres (MI). Two quantitative indexes of perfusion, fractional brain uptake (FBU) and normalized (with cerebellum) brain uptake (NBU), were also evaluated. Two SPECT studies were performed on seven cardiovascular patients who had no signs of neurological disease. In the first of these, 99mTc-bicisate was used, while in the other, which was performed 2 days later, MI were injected into the left heart ventricle. The values of the FBU, NBU, and Ki of 99mTc-bicisate were calculated in several gray and white matter brain regions of interest (ROIs) and compared with the rCBF values measured with MI in coupled ROIs. Mean FBU values were 0.00008 +/- 0.00002 and 0.00004 +/- 0.00001 in the gray and the white matter, respectively. Mean NBU values were 0.99 +/- 0.04 and 0.54 +/- 0.05, mean Ki values were 0.36 +/- 0.06 and 0.19 +/- 0.03 ml g-1 min-1 and mean rCBF values were 0.51 +/- 0.04 and 0.27 +/- 0.04 ml g-1 min-1 in gray and white matter, respectively. Analysis of variance of the regression gave different F values for the regressions with rCBF of FBU (F = 19, n = 126), NBU (F = 289, n = 112), and Ki (F = 117, n = 126).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Brain/diagnostic imaging , Cerebrovascular Circulation , Cysteine/analogs & derivatives , Organotechnetium Compounds , Tomography, Emission-Computed, Single-Photon , Aged , Analysis of Variance , Evaluation Studies as Topic , Female , Humans , Male , Microspheres , Middle Aged , Tissue Distribution
6.
Br J Pharmacol ; 91(2): 299-306, 1987 Jun.
Article in English | MEDLINE | ID: mdl-3607358

ABSTRACT

The prophylactic action of meptazinol against physostigmine- and neostigmine-induced lethality was evaluated in mice. Meptazinol proved to be effective against physostigmine (1 mg kg-1 i.p.), but not against neostigmine (0.5 mg kg-1 i.p.). The antagonism by meptazinol of physostigmine-induced poisoning was maximal when the drug was administered 15 min before physostigmine. Under these conditions the ED50 (95% confidence limits) of meptazinol was 24 (22.0-26.1) mg kg-1 s.c. A 30 mg kg-1 dose of the drug prevented lethality in 89% of the animals. The action of meptazinol was not antagonized by naloxone hydrochloride (2 mg kg-1 i.p.), injected 10 min before meptazinol. Pretreatment of mice with 30 mg kg-1 meptazinol 15 min before physostigmine (1 mg kg-1) poisoning increased brain acetylcholinesterase (AChE) activity on average, from 8 to 31% of control values. The protection of cholinesterases against physostigmine- and neostigmine-induced inactivation was demonstrated in vitro directly on purified preparations of the enzymes using a dilution method. The ED50 values (95% confidence limits) for the protective effect of meptazinol of electric eel AChE against 1 and 3 microM physostigmine and 1 microM neostigmine were 2.6 (1.4-4.9), 9.5 (5-18) and 3 (1.6-5.7) microM, respectively, while for protection of horse serum butyrylcholinesterase (BuChE) against the same inhibitors, the ED50 values were 12 (5.4-26.4), 42 (27-65.1) and 8 (3.6-17.6) microM, respectively. It is suggested that prevention of physostigmine-induced lethality by meptazinol is a consequence of its protective action on AChE in the central nervous system.


Subject(s)
Azepines/pharmacology , Meptazinol/pharmacology , Physostigmine/antagonists & inhibitors , Acetylcholinesterase/metabolism , Animals , Brain/drug effects , Brain/enzymology , Butyrylcholinesterase/metabolism , Electrophorus , Horses , In Vitro Techniques , Male , Meptazinol/administration & dosage , Mice , Neostigmine/antagonists & inhibitors , Physostigmine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...